A study to determine the efficacy and safety of finerenone on morbidity and mortality among hospitalized heart failure patients (REDEFINE-HF)
A study to determine the efficacy and safety of finerenone on morbidity and mortality among hospitalized heart failure patients (REDEFINE-HF)
ClinicalTrials.gov ID: NCT06008197
Sponsor: Colorado Prevention Center
Information provided by: Colorado Prevention Center (Responsible Party)
Last Update Posted: 2024-03-01
Brief Summary:
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
Detailed Description:
This is an international, randomized, double-blind, placebo-controlled, event-driven trial of finerenone for the treatment hospitalized heart failure patients with mildly reduced or preserved ejection fraction.
Official Title:
Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)
| Category | Value |
|---|---|
| Study Start (Actual) |
2024-01-17
|
| Primary Completion (Estimated) |
2026-04-01
|
| Study Completion (Estimated) |
2026-04-01
|
| Enrollment (Estimated) | 5200 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers | 202301CPC |